Pharma channel feed

Bi­par­ti­san group of law­mak­ers seeks to reign in phar­ma patent thick­ets with new bill

Last year
FDA+

J&J still plans to scale up Carvyk­ti man­u­fac­tur­ing this year as it awaits FDA de­ci­sion on ex­pan­sion to ear­li­er lines

Last year
Manufacturing

Mar­ket­ingRx roundup: Pfiz­er re­ups ba­by check­up cam­paign on so­cials; BI, Take­da on top em­ploy­ers list

Last year
Marketing

J&J meets Q4 ex­pec­ta­tions with $21.4B in sales as it stares down patent cliff

Last year

Gene edit­ing de­liv­ery biotech GenEd­it part­ners with Genen­tech, rais­es an­oth­er $24M

Last year
Financing
Startups

Up­dat­ed: FDA’s safe­ty re­view on CAR-Ts cul­mi­nates in new boxed warn­ings of sec­ondary can­cer

Last year
Cell/Gene Tx
FDA+

Au­to­lus eyes No­vem­ber for po­ten­tial US ap­proval of Tecar­tus ri­val

Last year
Cell/Gene Tx
FDA+

FDA high­lights pri­or­i­ty re­view vouch­ers re­deemed as reau­tho­riza­tion lingers in Con­gress

Last year
FDA+

Neu­ro com­pa­nies are one of phar­ma's hottest M&A as­sets. But be­hind the scenes, there have been few bid­ders

Last year
Deals

No­var­tis' TV ad for breast can­cer drug Kisqali draws un­ti­tled let­ter from FDA

Last year
FDA+
Marketing

In bid to ex­tend cash run­way, Cara to lay off work­ers, dis­con­tin­ue PhI­II pro­gram in chron­ic kid­ney dis­ease

Last year
People

Lack­lus­ter da­ta on Alzheimer's drugs lead to end of Roche-AC Im­mune part­ner­ship

Last year
Deals
R&D

Co­herus sells San­doz its Lu­cen­tis biosim­i­lar for $170M to fo­cus on on­col­o­gy as­sets 

Last year
Deals

Ap­n­imed hires Pfiz­er, Bio­haven vet­er­an as chief com­mer­cial of­fi­cer

Last year
People
Marketing

J&J wins full ap­proval for blad­der can­cer drug

Last year
FDA+

De­San­tis, John­son raise flags around Covid boost­ers as FDA main­tains that they're safe and ef­fec­tive

Last year
FDA+

As­traZeneca's rare blood dis­or­der pill ap­proved in Japan

Last year
FDA+

Cannes Li­ons taps Edel­man, Dentsu ex­ecs to lead the phar­ma, health and well­ness ju­ries

Last year
Marketing

As­traZeneca, Boehringer In­gel­heim, GSK de­fend patent list­ings as Klobuchar amps up pres­sure

Last year
FDA+

Lund­beck en­cour­ages mi­graine pa­tients to ‘Say Yep’ to its IV-in­fused med in lat­est cam­paign

Last year
Marketing

New­ly hope­ful, bio­phar­ma still faces an un­cer­tain 2024

Last year
Financing

Sen­a­tor ques­tions CVS, Wal­greens about growth in 340B par­tic­i­pa­tion

Last year
Law

GSK sells par­tial stake of con­sumer health spin­off Ha­le­on for $1.2B

Last year

Sen­ate health com­mit­tee to vote on rare sub­poe­nas for J&J and Mer­ck CEOs over drug pric­ing tes­ti­mo­ny

Last year
Law
First page Previous page 78798081828384 Next page Last page
A service from the Financial Times